Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes
Open Access
Abstract
Objective: This study aimed to estimate population‐level effects on weight change of initiating/adhering to additional glucose‐lowering medications in adults with type 2 diabetes prescribed metformin. Methods: We conducted a target trial using electronic health record data from 22,601 patients (age 20 to < 80 years) prescribed metformin to determine initiation/adherence to dipeptidyl peptidase IV (DPP4) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors, long‐acting insulin, or sulfonylureas. Inverse probability weighting of marginal structural models with standardization by baseline covariates was used to estimate population‐level effects of initiating/adhering to different medications on average 24‐month weight change. Results: At 24 months, a mean −5.15 kg (95% CI −10.6, −1.36) and −6.71 kg (95% CI −8.38, −4.34) weight loss would be observed for initiation/adherence to GLP‐1RAs and SGLT‐2s respectively. At 6 months, weight loss for DPP4s would be observed (−0.89 kg, 95% CI −1.41, −0.32) though not at 12 or 24 months. Glimepiride would be associated with weight gain at 6 and 12 months (0.88 kg, 95% CI 0.44, 1.22; 1.01 kg, 95% CI 0.32, 1.51) but not at 24 months. Conclusions: Initiation/adherence to GLP‐1RAs and SGLT‐2s over 24 months could result in average weight losses of 5.15 kg and 6.71 kg, respectively.Keywords
Funding Information
- Agency for Healthcare Research and Quality (T32HS026122)
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK120598)
- National Center for Advancing Translational Sciences (5KL2TR002245)
This publication has 38 references indexed in Scilit:
- Emulating Target Trials Comparing Early and Delayed Intubation StrategiesChest, 2023
- Translating questions to estimands in randomized clinical trials with intercurrent eventsStatistics in Medicine, 2022
- PCORnet® 2020: current state, accomplishments, and future directionsJournal of Clinical Epidemiology, 2021
- Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpointsDiabetes & Metabolism, 2020
- Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world ApproachCurrent Diabetes Reports, 2018
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trialThe Lancet, 2018
- Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective StudyDiabetes Therapy, 2016
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measuresStatistics in Medicine, 2002